D.A. Davidson & CO. Buys 6,725 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)

D.A. Davidson & CO. increased its stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) by 8.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 88,450 shares of the company’s stock after acquiring an additional 6,725 shares during the quarter. D.A. Davidson & CO. owned approximately 0.06% of Adaptive Biotechnologies worth $530,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Ashton Thomas Securities LLC bought a new position in Adaptive Biotechnologies during the 3rd quarter worth approximately $34,000. KBC Group NV bought a new stake in shares of Adaptive Biotechnologies in the 4th quarter worth approximately $50,000. GAMMA Investing LLC bought a new stake in shares of Adaptive Biotechnologies in the 4th quarter worth approximately $59,000. Townsquare Capital LLC bought a new stake in shares of Adaptive Biotechnologies in the 3rd quarter worth approximately $56,000. Finally, Centiva Capital LP bought a new stake in shares of Adaptive Biotechnologies in the 3rd quarter worth approximately $80,000. 99.17% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO Chad M. Robins sold 99,107 shares of Adaptive Biotechnologies stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $8.44, for a total value of $836,463.08. Following the completion of the sale, the chief executive officer now owns 2,576,701 shares of the company’s stock, valued at $21,747,356.44. The trade was a 3.70 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold 469,188 shares of company stock valued at $3,975,795 over the last 90 days. Company insiders own 6.20% of the company’s stock.

Adaptive Biotechnologies Price Performance

Shares of ADPT opened at $8.42 on Wednesday. Adaptive Biotechnologies Co. has a one year low of $2.28 and a one year high of $8.95. The firm has a market capitalization of $1.24 billion, a P/E ratio of -7.72 and a beta of 1.49. The business has a fifty day moving average of $7.27 and a 200 day moving average of $5.85.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.04. Adaptive Biotechnologies had a negative return on equity of 64.65% and a negative net margin of 89.12%. During the same period last year, the company earned ($0.30) earnings per share. Analysts expect that Adaptive Biotechnologies Co. will post -0.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. BTIG Research lifted their price objective on Adaptive Biotechnologies from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. The Goldman Sachs Group raised their target price on Adaptive Biotechnologies from $5.50 to $7.50 and gave the company a “neutral” rating in a research note on Tuesday, January 28th. Scotiabank raised their target price on Adaptive Biotechnologies from $10.00 to $12.00 and gave the company a “sector outperform” rating in a research note on Thursday, February 13th. Finally, Piper Sandler restated an “overweight” rating and issued a $11.00 target price (up previously from $7.00) on shares of Adaptive Biotechnologies in a research note on Thursday, February 20th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $9.10.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.